MRA Countdown: 10, 6, 4, 2, ...
Recommendation

17/18 June 2026
Copenhagen, Denmark
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The Mutual Recognition Agreement (MRA) with the US is on track. In a press announcement from 11 June the EMA informed that Luxembourg and the Netherlands have joined the agreement for good manufacturing practice (GMP) inspections between the US Food and Drug Administration (FDA) and EU Member States.
Now 26 countries are included. Germany and Slovakia are the only EU member states that have not been added yet. By 15 July 2019, however, all authorities and countries should have been approved and acknowledged by FDA.
If the agreement is in force (and only then!), the additional full testing of a drug imported from the USA will no longer be necessary. This also applies to countries that have already been recognised.
Source: EMA press release entitled "Two additional countries to benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
03.06.2026GMP Auditor Association Developments January through April 2026
20.05.2026CAPA and Root Cause Analysis - why FDA keeps calling them out
20.05.2026FDA Pilots One-Day Inspectional Assessments to Expand Oversight
06.05.2026FDA Warning Letter: CAPA not only needed for Deviations
28.04.2026FDA remains active in Europe - further Inspections despite MRAs


